Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide

Archives of Dermatology

Volumn 145, Issue 9, 2009, Pages 1027-1029

  Dubina, Meghan I ^a   Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; DAPSONE; RETINOIC ACID; SULFACETAMIDE; TAZAROTENE;

ACNE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; PRIORITY JOURNAL; SKIN DISCOLORATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; BENZOYL PEROXIDE; DAPSONE; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; SKIN; SULFACETAMIDE;

EID: 70349314921     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.186     Document Type: Article

References (19)

1. Fleischer AB Jr, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol. 1994;102(1):93-97.
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3)(suppl):S200-S210.
3. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2, pt 3):S17-S24.
4. Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and treatment of acne. Am Fam Physician. 2004;69(9):2123-2130.
5. Fleischer AB, Draelos ZD, Abramovits W, Pariser DM. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double-blind study. J Am Acad Dermatol. 2007;56:AB16.
6. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001;19(1):79-86, viii.
7. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420-434.
8. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961;73:367-370.
9. Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol. 1988;13(2):67-71. (Pubitemid 18199505)
10. Wolf R, Matz H, Orion E, Tuzun B, Tuzun Y. Dapsone. Dermatol Online J. 2002;8(1):2.
11. Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46(8):697-712. (Pubitemid 47204855)
12. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. New York, NY: Churchill Livingstone Inc; 2000.
13. Burkhart CG, Burkhart CN. Antibacterial properties of benzoyl peroxide in aerobic and anaerobic conditions. Int J Dermatol. 2006;45(11):1373-1374.
14. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4(7):473-492. (Pubitemid 36871766)
15. Burkhart CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol. 2000;13(5):292-296. (Pubitemid 30666028)
16. Burkhart CG, Burkhart CN. Antibacterial properties of soluble benzoyl peroxide. Int J Dermatol. 2008;47(3):301-302.
17. Burkhart CG, Burkhart CN, Isham N. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. Br J Dermatol. 2006;154(2):341-344. (Pubitemid 43382708)
18. Burkhart CG, Burkhart CN. Treatment of acne vulgaris without antibiotics: tertiary amine-benzoyl peroxide combination vs. benzoyl peroxide alone (Proactiv Solution). Int J Dermatol. 2007;46(1):89-93.
19. Burkhart CG, Burkhart CN. Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide. Dermatol Surg. 2005;31(11, pt 1):1479-1480.